


IMPACT
FACTOR
4.073




marine drugs

an Open Access Journal by MDPI



Academic Open Access Publishing
since 1996

Australia New Zealand Marine Biotechnology Society
(ANZMBS) is affiliated with *Marine Drugs*



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Orazio Tagliatalata-Scafati









Associate Editors

Prof. Dr. Anake Kijjoa
Prof. Dr. Vassilios Roussis
Prof. Dr. Claudiu T. Supuran
Dr. Hitoshi Sashiwa
Prof. Dr. Marialuisa Menna
Dr. Ipek Kurtboke
Prof. Dr. Bill J. Baker
Prof. Dr. Marc Diederich

Message from the Editor-in-Chief

The marine environment has become a recognized source for the discovery of bioactive compounds, as testified by the solid preclinical/clinical pipeline that currently exists for marine-derived products. *Marine Drugs* is inviting contributions on new advances in marine natural product chemistry, marine biotechnology, marine pharmacology and genomics related to the discovery of biologically and therapeutically relevant marine natural products. Our goal is to share sound contributions in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

-  **Open Access** Unlimited and free access for readers
-  **No Copyright Constraints** Retain copyright of your work and free use of your article
-  **Thorough Peer-Review**
-  **Rapid Publication** A first decision provided to authors approximately 12.3 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2020)
-  **Coverage by Leading Indexing Services** SCIE-Science Citation Index Expanded (Clarivate Analytics), PubMed (NLM), MEDLINE (NLM), Scopus (Elsevier), MarinLit (RSC)
-  **No Space Constraints, No Extra Space or Color Charges** No restriction on the length of the papers, number of figures or colors
-  **Discounts on Article Processing Charges (APC)** If you belong to an institute that participates with the MDPI Institutional Open Access Program (IOAP)
-  **Impact Factor 4.073** (2019 Journal Citation Reports®)

Aims and Scope

Marine Drugs (ISSN 1660-3397) publishes peer-reviewed research papers, short notes, and reviews reporting on the discovery, development, exploitation, and production of biologically and therapeutically active compounds from marine habitats.

Identification of bioactive compounds from marine microorganisms, invertebrates, fishes, and plants
Pharmacological characterization of marine compounds or their derivatives
Marine natural products with activity against human, animal and plant diseases
Marine natural products with insecticidal or herbicidal activities
Synthesis, mutasynthesis and medicinal chemistry of marine natural products
Marine proteomics, glycomics, and lipidomics related to drug discovery or bioactivity
Marine drug development, including pharmaceutical formulation and clinical trials
Marine chemical ecology research inspiring marine drug discovery
Innovative sampling and isolation techniques targeting bioactive marine natural products
Marine biotechnology and molecular biology studies related to drug discovery or production
Structural and biological characterization of marine toxins
Biomaterials of marine origin
Marine-derived ingredients for cosmeceuticals, nutraceuticals, marine-derived functional foods and nutritional supplements

Editorial Office

Marine Drugs Editorial Office
marinedrugs@mdpi.com
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/marinedrugs

MDPI is a member of



Affiliated Societies




Follow Us

 facebook.com/MDPIOpenAccessPublishing

 twitter.com/MDPIOpenAccess

 linkedin.com/company/mdpi

 weibo.com/mdpicn

 Wechat: MDPI-China

 blog.mdpi.com



www.mdpi.com

mdpi.com/journal/marinedrugs

See www.mdpi.com for a full list of offices and contact information. MDPI is a company registered in Basel, Switzerland, No. CH-270.3.014.334-3, whose registered office is at St. Alban-Anlage 66, CH-4052 Basel, Switzerland.

Basel, January 2021